Drug
SB939 compound clinical trials
Also written SB939 and Pracinostat.
- studies test it
- 14
- open now
- 0
- in phase 3
- 1
- first study started
- 2007
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 4 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 7
Helsinn Healthcare SA (7) · NCIC Clinical Trials Group (4) · M.D. Anderson Cancer Center (2) · Medical College of Wisconsin (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses SB939 compound is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and LeukemiaCompletedPhase 1NCIC Clinical Trials GroupNCT01184274Written as SB939
- SB939 in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1NCIC Clinical Trials GroupNCT00504296Written as HDAC inhibitor SB939
- SB939 in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedPhase 2NCIC Clinical Trials GroupNCT01075308Written as HDAC inhibitor SB939
- A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic SarcomasCompletedPhase 2NCIC Clinical Trials GroupNCT01112384Written as SB939
- Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedPhase 1Medical College of WisconsinNCT03848754Written as Pracinostat - 45 mg
- An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid LeukemiaTerminatedPhase 3Helsinn Healthcare SANCT03151408Written as Pracinostat
- A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic SyndromesTerminatedPhase 2Helsinn Healthcare SANCT03151304Written as Pracinostat
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedPhase 2Helsinn Healthcare SANCT01912274Written as Pracinostat
- A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The BodyCompletedPhase 1Helsinn Healthcare SANCT03495934Written as pracinostat
- Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)CompletedPhase 2M.D. Anderson Cancer CenterNCT02267278Written as Pracinostat
- Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic SyndromeCompletedPhase 2Helsinn Healthcare SANCT01873703Written as pracinostat
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMACompletedPhase 2Helsinn Healthcare SANCT01993641Written as pracinostat
- Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult SubjectsCompletedEarly Phase 1Helsinn Healthcare SANCT02058784Written as pracinostat
- Study of SB939 in Subjects With MyelofibrosisCompletedPhase 2M.D. Anderson Cancer CenterNCT01200498Written as SB939
Given in every arm · 2 — SB939 compound is usual care beside what is tested
- Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking SubjectsCompletedPhase 1Helsinn Healthcare SANCT02118909Written as Pracinostat
- A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With AzacitidineCompletedPhase 1S*BIONCT00741234Written as SB939